


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-10.95%
+2.43%
+1.62%
+34.90%
+2.13%
XCUR
Exicure
$6.07
XCUR Price Performance
$4.17 (+45.56%)
$3.84 (+58.07%)
$7.85 (-22.68%)
$17.25 (-64.81%)
XCUR has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

XCUR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
![]()
XCUR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
XCUR Street Sentiment is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is XCUR current stock price?
What are XCUR stock strengths?
What is XCUR Risk Level?
What is XCUR market cap and volume?
What is XCUR current Stock IQ?
Should I buy XCUR stock right now?
Is XCUR a Strong Buy right now?
What does a 'Strong Buy' rating mean for XCUR?
What does a 'Strong Sell' rating mean for XCUR?
What factors influence XCUR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-10.95%
+2.43%
+1.62%
+34.90%
+2.13%
XCUR
Exicure
Current Price
$6.07

XCUR Price Performance
$4.17 (+45.56%)
$3.84 (+58.07%)
$7.85 (-22.68%)
$17.25 (-64.81%)
XCUR Analysts Opinion
XCUR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
![]()
XCUR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
XCUR Street Sentiment is extremely bullish and have negative views on the near-term outlook
XCUR has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
XCUR Stock IQ
XCUR Latest Analysis
Exicure Shares Surge 41% On Promising Phase 2 Data For Multiple Myeloma Drug . (RTTNews) - Exicure Inc. (XCUR) skyrocketed 41.37% adding $2.18 to trade at $7.45 after the company announced positive topline results from its Phase 2 study of burixafor in multiple myeloma.
Tue Dec 9, 2025
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial. ) stock is trading higher on Tuesday. Its session volume was 13.62 million compared with the average volume of 151.41 thousand according to .The company shared results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in multiple myeloma patients undergoing .The data showed that appro
Tue Dec 9, 2025
Exicure Soars On Burixafor Data In Multiple Myeloma Trial . (RTTNews) - Shares of Exicure Inc. (XCUR) were up over 65% at $8.69 in overnight trading following the presentation of positive topline phase 2 data for Burixafor in multiple myeloma at the ASH Annual Meeting yesterday.
Tue Dec 9, 2025
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting. REDWOOD CITY Calif. Dec. 08 2025 (GLOBE NEWSWIRE) -- Exicure Inc. (Nasdaq: XCUR) a clinical-stage biotechnology company developing therapeutics for hematologic diseases today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic proge
Mon Dec 8, 2025
Exicure stock soars after positive Phase 2 data for multiple myeloma drug.
Mon Dec 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
XCUR Stock trends
XCUR Stock performance
XCUR Stock analysis
XCUR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.